Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.

Launched by ELPEN PHARMACEUTICAL CO. INC. · Jul 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a combination treatment using two medications, solifenacin and tamsulosin, on men with benign prostatic hyperplasia (BPH), a condition that causes the prostate gland to enlarge and leads to uncomfortable urinary symptoms. The research aims to see how well this treatment helps control the disease and improves the quality of life for patients experiencing moderate to severe symptoms.

To participate in the study, you need to be a male adult who has been diagnosed with BPH and has not found relief with their current treatment. You'll also need to understand the study procedures and agree to participate by signing a consent form. If you join, you'll be monitored by your doctor as they continue their routine care, and your experiences with the treatment will be evaluated to help understand its effectiveness for others in similar situations. This trial is currently recruiting participants, and it aims to gather valuable information about how this specific combination therapy can help men suffering from BPH.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male adult patient with moderate to severe symptoms of BPH receiving monotherapy and not responding adequately.
• • Male adult patient with BPH who has fully understood the study procedures and signed an informed consent form.
• Exclusion Criteria:
• • -